Publicação:
N-acetylglucosaminidase, myeloperoxidase and vascular endothelial growth factor serum levels in breast cancer patients

dc.contributor.authorCoelho, Bertha Andrade [UNESP]
dc.contributor.authorBelo, Andrezza Vilaca
dc.contributor.authorAndrade, Silvia Passos
dc.contributor.authorAmorim, Washington Cancado
dc.contributor.authorUemura, Gilberto [UNESP]
dc.contributor.authorSilva Filho, Agnaldo Lopes da [UNESP]
dc.contributor.institutionUniversidade Estadual Paulista (Unesp)
dc.contributor.institutionUniversidade Federal de Minas Gerais (UFMG)
dc.date.accessioned2014-12-03T13:10:33Z
dc.date.available2014-12-03T13:10:33Z
dc.date.issued2014-03-01
dc.description.abstractInflammatory cells surround breast carcinomas and may act promoting tumor development or stimulating anti-tumor immunity. N-acetylglucosaminidase (NAG) has been employed to detect macrophage accumulation/activation. Myeloperoxidase (MPO) is considered a marker for neutrophils activity/accumulation. Vascular Endothelial Growth Factor (VEGF) is as strong pro-angiogenic cytokine. The aim of this study was to measure the systemic inflammatory response by measuring serum levels of NAG, MPO and VEGF in women diagnosed with breast cancer and associate this response to the peritumoral inflammatory infiltrate and to prognostic factors. Serum samples obtained from women with no evidence of disease (n = 31) and with breast cancer (n = 68) were analyzed for the activities of NAG, MPO and VEGF by enzymatic assay. Serum levels of NAG and VEGF were higher in healthy volunteers (P < 0.0001) and serum levels of MPO were higher in patients with breast cancer (P = 0.002). Serum levels of NAG were positively correlated to serum levels of MPO and VEGF (P < 0.0001 and P = 0.0012, respectively) and MPO and VEGF serum levels had also a positive correlation (P = 0.0018). The inflammatory infiltrate was not associated to serum levels of the inflammatory markers, and higher levels of MPO were associated to lymphovascular invasion negativity (P = 0.0175). (C) 2013 Elsevier Masson SAS. All rights reserved.en
dc.description.affiliationUniv Estadual Paulista, UNESP, Fac Med, Dept Gynecol & Obstet, BR-618970 Botucatu, SP, Brazil
dc.description.affiliationUniv Fed Minas Gerais, Fac Med, Dept Gynecol & Obstet, Belo Horizonte, MG, Brazil
dc.description.affiliationUniv Fed Minas Gerais, Dept Physiol & Pharmacol, Belo Horizonte, MG, Brazil
dc.description.affiliationUnespUniv Estadual Paulista, UNESP, Fac Med, Dept Gynecol & Obstet, BR-618970 Botucatu, SP, Brazil
dc.format.extent185-189
dc.identifierhttp://dx.doi.org/10.1016/j.biopha.2013.10.009
dc.identifier.citationBiomedicine & Pharmacotherapy. Paris: Elsevier France-editions Scientifiques Medicales Elsevier, v. 68, n. 2, p. 185-189, 2014.
dc.identifier.doi10.1016/j.biopha.2013.10.009
dc.identifier.issn0753-3322
dc.identifier.lattes9878648143577124
dc.identifier.urihttp://hdl.handle.net/11449/112243
dc.identifier.wosWOS:000333423600007
dc.language.isoeng
dc.publisherElsevier B.V.
dc.relation.ispartofBiomedicine & Pharmacotherapy
dc.relation.ispartofjcr3.457
dc.relation.ispartofsjr0,951
dc.rights.accessRightsAcesso restrito
dc.sourceWeb of Science
dc.subjectN-acetylglucosaminidase (NAG)en
dc.subjectMyeloperoxidase (MPO)en
dc.subjectVascular Endothelial Growth Factor (VEGF)en
dc.titleN-acetylglucosaminidase, myeloperoxidase and vascular endothelial growth factor serum levels in breast cancer patientsen
dc.typeArtigo
dcterms.licensehttp://www.elsevier.com/about/open-access/open-access-policies/article-posting-policy
dcterms.rightsHolderElsevier B.V.
dspace.entity.typePublication
unesp.author.lattes9878648143577124
unesp.campusUniversidade Estadual Paulista (Unesp), Faculdade de Medicina, Botucatupt
unesp.departmentGinecologia e Obstetrícia - FMBpt

Arquivos